{"id":2914,"date":"2018-09-14T14:38:54","date_gmt":"2018-09-14T14:38:54","guid":{"rendered":"https:\/\/lynxee.consulting\/?p=2914\/"},"modified":"2023-01-26T14:45:37","modified_gmt":"2023-01-26T14:45:37","slug":"europe-efsa-recurring-issues-in-mammalian-toxicology-2","status":"publish","type":"post","link":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/","title":{"rendered":"EUROPE &#8211; EFSA: Recurring issues in mammalian toxicology"},"content":{"rendered":"<p>During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were identified by EFSA that needed discussion with experts from National Authorities in order to enhance the harmonisation of the risk assessment of active substances.<\/p>\n<p>A new discussion was held at the <i>Pesticide Peer Review Meeting 170<\/i> of December 2017. Recommendations were made on:<\/p>\n<ul>\n<li>Genotoxicity of plant protection products<\/li>\n<li>Use of (Q)SARs<\/li>\n<li>Use of Read-Across approaches for metabolites<\/li>\n<\/ul>\n<p>These recommendations will be applied during the EFSA peer review of the active substances.<\/p>\n<p>&nbsp;<\/p>\n<p>In addition, brief discussions of the following topics were also made:<\/p>\n<ul>\n<li>EFSA guidance 2016 on the residue definition<\/li>\n<li>EFSA guidance 2017 on dermal absorption<\/li>\n<li>Current and planned EFSA activities in the area of pesticides:\n<ul>\n<li>Developmental neurotoxicity<\/li>\n<li>Cumulative assessment groups<\/li>\n<li>Epidemiology<\/li>\n<li>Planned workshops (<i>in vitro<\/i> comparative metabolism, phototoxicity, historical control data)<\/li>\n<li>Update of EFSA guidance 2014 on the assessment of exposure of operators, workers, residents and bystanders<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><b>To download: <\/b><\/p>\n<p><a href=\"https:\/\/efsa.onlinelibrary.wiley.com\/doi\/epdf\/10.2903\/sp.efsa.2018.EN-1485\" target=\"_blank\" rel=\"noopener noreferrer\">EFSA Technical Report \u2013 Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology<\/a> (25 August 2018)<\/p>\n<p>&nbsp;<\/p>\n<p><b>See also our previous articles: <\/b><\/p>\n<p><a href=\"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology\/\" target=\"_blank\" rel=\"noopener noreferrer\">EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><b>Lynxee consulting<\/b>\u2019s team is at your disposal to answer your questions.<\/p>\n<p><b>Contact us!<\/b> <a href=\"https:\/\/lynxee.consulting\/en\/contact\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/lynxee.consulting\/en\/contact\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h6>Photo credit: PublicDomainPictures\/pixabay<\/h6>\n","protected":false},"excerpt":{"rendered":"<p>During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were identified by EFSA<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":7,"featured_media":1848,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[143,195],"class_list":["post-2914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulation","tag-efsa","tag-human-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EUROPE - EFSA: Recurring issues in mammalian toxicology - Lynxee consulting<\/title>\n<meta name=\"description\" content=\"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUROPE - EFSA: Recurring issues in mammalian toxicology - Lynxee consulting\" \/>\n<meta property=\"og:description\" content=\"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Lynxee consulting\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-14T14:38:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-26T14:45:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2016\/08\/dna-163466_1280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Adrien Margerit\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adrien Margerit\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/\"},\"author\":{\"name\":\"Adrien Margerit\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/8bd656ad92ca721913ddf5433730d240\"},\"headline\":\"EUROPE &#8211; EFSA: Recurring issues in mammalian toxicology\",\"datePublished\":\"2018-09-14T14:38:54+00:00\",\"dateModified\":\"2023-01-26T14:45:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/\"},\"wordCount\":224,\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2016\\\/08\\\/dna-163466_1280.jpg\",\"keywords\":[\"EFSA\",\"Human Health\"],\"articleSection\":[\"Regulation\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/\",\"name\":\"EUROPE - EFSA: Recurring issues in mammalian toxicology - Lynxee consulting\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2016\\\/08\\\/dna-163466_1280.jpg\",\"datePublished\":\"2018-09-14T14:38:54+00:00\",\"dateModified\":\"2023-01-26T14:45:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/8bd656ad92ca721913ddf5433730d240\"},\"description\":\"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\\\/2009, several aspects in the area of mammalian toxicology were\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2016\\\/08\\\/dna-163466_1280.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2016\\\/08\\\/dna-163466_1280.jpg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUROPE &#8211; EFSA: Recurring issues in mammalian toxicology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/\",\"name\":\"Lynxee consulting\",\"description\":\"Innovative support for regulatory issues\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lynxee.consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/8bd656ad92ca721913ddf5433730d240\",\"name\":\"Adrien Margerit\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/AMA_WP-96x96.jpg\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/AMA_WP-96x96.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/AMA_WP-96x96.jpg\",\"caption\":\"Adrien Margerit\"},\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/author\\\/adrien-margerit\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUROPE - EFSA: Recurring issues in mammalian toxicology - Lynxee consulting","description":"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/","og_locale":"en_US","og_type":"article","og_title":"EUROPE - EFSA: Recurring issues in mammalian toxicology - Lynxee consulting","og_description":"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were","og_url":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/","og_site_name":"Lynxee consulting","article_published_time":"2018-09-14T14:38:54+00:00","article_modified_time":"2023-01-26T14:45:37+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2016\/08\/dna-163466_1280.jpg","type":"image\/jpeg"}],"author":"Adrien Margerit","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adrien Margerit","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/#article","isPartOf":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/"},"author":{"name":"Adrien Margerit","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240"},"headline":"EUROPE &#8211; EFSA: Recurring issues in mammalian toxicology","datePublished":"2018-09-14T14:38:54+00:00","dateModified":"2023-01-26T14:45:37+00:00","mainEntityOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/"},"wordCount":224,"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2016\/08\/dna-163466_1280.jpg","keywords":["EFSA","Human Health"],"articleSection":["Regulation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/","url":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/","name":"EUROPE - EFSA: Recurring issues in mammalian toxicology - Lynxee consulting","isPartOf":{"@id":"https:\/\/lynxee.consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/#primaryimage"},"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2016\/08\/dna-163466_1280.jpg","datePublished":"2018-09-14T14:38:54+00:00","dateModified":"2023-01-26T14:45:37+00:00","author":{"@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240"},"description":"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were","breadcrumb":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/#primaryimage","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2016\/08\/dna-163466_1280.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2016\/08\/dna-163466_1280.jpg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lynxee.consulting\/en\/"},{"@type":"ListItem","position":2,"name":"EUROPE &#8211; EFSA: Recurring issues in mammalian toxicology"}]},{"@type":"WebSite","@id":"https:\/\/lynxee.consulting\/#website","url":"https:\/\/lynxee.consulting\/","name":"Lynxee consulting","description":"Innovative support for regulatory issues","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lynxee.consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240","name":"Adrien Margerit","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg","caption":"Adrien Margerit"},"url":"https:\/\/lynxee.consulting\/en\/author\/adrien-margerit\/"}]}},"_links":{"self":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/comments?post=2914"}],"version-history":[{"count":4,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2914\/revisions"}],"predecessor-version":[{"id":6296,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2914\/revisions\/6296"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media\/1848"}],"wp:attachment":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media?parent=2914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/categories?post=2914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/tags?post=2914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}